Guido van Rossum wrote Python over a 1989 Christmas break. By 2018 it ran AI and the web, and a fight over the walrus ...

Tutorials, Guides and Agent Skills Directories. Contribute to federicodeponte/awesome-agent-skills-1 development by creating an account on GitHub.

In the table below, we highlight the cost, length and strength of the best prompt engineering course providers. This table ...

The best documentaries don't feel like documentaries. They have a connotation of being educational, but even career documentarians will tell you that all they're doing is telling a story just like any ...

Anthropic has moved Code Review, its automated pull-request reviewer for Claude Code, out of research preview for Team and Enterprise customers, with up to $50,000 in free credits for eligible ...

For a change, the Pittsburgh Steelers’ offense didn’t do much to make the fanbase mad Sunday. Based on my interactions with readers this week, the defensive pass rush has that covered. The Pirates ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Federal and state regulators asked a federal judge Tuesday to hold Martin Shkreli in contempt, saying he has traded pharmaceutical stocks on YouTube for years in violation of a lifetime ban from the ...

Federal regulators and several state attorneys general have accused Martin Shkreli of violating his lifetime ban from the pharmaceutical industry. Shkreli was banned in 2022 after a conviction for an ...

The Federal Trade Commission (FTC) and a coalition of seven states asked a federal court on Tuesday to punish Martin Shkreli for “flagrantly and repeatedly” violating a lifetime ban from being ...

“Pharma Bro” Martin Shkreli has caught the attention of federal and state authorities again. Since his 2022 release from prison for securities fraud, Shkreli — who gained national notoriety for ...

Martin Shkreli, a former hedge-fund manager known as “Pharma Bro,” is back in the crosshairs of U.S. regulators for influencing biopharma stocks even though he is banned from being involved with the ...